☆ 4.6 Review

Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

CANCERS (2023)

Related references

Note: Only part of the references are listed.

Review Orthopedics

Is bisphosphonate use a risk factor for atypical periprosthetic/peri-implant fractures?-A metanalysis of retrospective cohort studies and systematic review of the current evidence

Pedro Ferreira et al.

Summary: This study confirmed the increased risk of atypical periprosthetic/peri-implant fractures in patients on long-term bisphosphonate therapy through a systematic review and meta-analysis. The results showed that bisphosphonates are a risk factor for the development of these fractures. However, the small size of available studies and risk of significant bias prevented reliable determination of other secondary outcomes. Clinicians should actively search for atypical fractures in patients on long-term bisphosphonate therapy when they present with non-specific pain near the implant/prosthesis or reduced mobility.

ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH (2023)

Add to Collection

Article Endocrinology & Metabolism

Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study

Marta Diaz-delCastillo et al.

Summary: Multiple myeloma is an incurable bone marrow cancer that leads to osteolytic lesions. Treatment often involves proteasome inhibitors, but their side effects and administration route limit long-term use. This study investigates the bone effects of ixazomib, a new-generation oral proteasome inhibitor, and suggests that it may promote bone formation by reducing bone resorption and promoting longer bone formation events.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Add to Collection

Article Endocrinology & Metabolism

A Critical Role of the Bone Marrow Envelope in Human Bone Remodeling

Thomas Levin Andersen et al.

Summary: Proper bone remodeling relies not only on the actions of osteoclasts and osteoblasts, but also on the delivery of osteoblast lineage cells to the remodeling site. A CD271-positive/PDGF beta-R-positive cell layer surrounding the bone marrow provides osteoblastogenic potential on all bone surfaces, including both quiescent and remodeling sites. This cell layer, known as the canopy, plays a critical role in initiating bone remodeling by activating early markers of osteoblastogenesis and supporting cell delivery to the bone surface.

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Add to Collection

Article Oncology

Global burden of hematologic malignancies and evolution patterns over the past 30 years

Nan Zhang et al.

Summary: Hematologic malignancies are common cancers and understanding their incidence and death rates is crucial. The study examined data from 1990 to 2019 and found that globally, incident cases of hematologic malignancies have been increasing while the death rates have been declining. However, there are variations in trends based on gender, age, region, and economic situation.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Review Dentistry, Oral Surgery & Medicine

Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis

Chengrong Zhang et al.

Summary: This study aimed to assess the incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab in bone cancer metastasis or adjuvant therapy. A total of 42,003 patients with various solid tumors were included. The overall incidence of ONJ in cancer patients receiving denosumab or bisphosphonates was 2.08%. Patients receiving denosumab had a higher incidence of ONJ compared to those receiving bisphosphonates. Prostate cancer patients receiving denosumab and zoledronic acid had the highest incidences of ONJ at 5.0% and 3.0%, respectively. The incidence of ONJ varied with different drug doses.

SPECIAL CARE IN DENTISTRY (2023)

Add to Collection

Letter Oncology

Potential value of pre-planned imaging of bone disease in multiple myeloma

Michael Gundesen et al.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Hematology

OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma

Michael Gundesen et al.

Clinical Lymphoma Myeloma & Leukemia (2023)

Add to Collection

Article Biology

The Ins and Outs of Endosteal Niche Disruption in the Bone Marrow: Relevance for Myeloma Oncogenesis

Jean-Pascal Capp et al.

Summary: Monoclonal gammopathy cases of unknown significance are mainly found in aging people and are the precursor to multiple myeloma. The bone microenvironment, specifically the endosteal niche, plays a critical role in the genesis of these diseases. Bone senescence and inflammaging cause a disruption of the endosteal niche and create a permissive microenvironment for the emergence and maintenance of gammopathy and myeloma.

BIOLOGY-BASEL (2023)

Add to Collection

Article Endocrinology & Metabolism

Trabecular bone deterioration in a postmenopausal female suffering multiple spontaneous vertebral fractures due to a delayed denosumab injection - A post-treatment re-initiation bone biopsy-based case study

Louise Alstrup Drejer et al.

Summary: This case report describes a patient with postmenopausal osteoporosis who experienced multiple vertebral fractures after discontinuing denosumab treatment. The study found that reinitiating denosumab treatment led to extensive bone resorption and delayed bone formation. This highlights the importance of developing optimal discontinuation strategies to prevent such complications.

BONE REPORTS (2023)

Add to Collection

Review Orthopedics

Is bisphosphonate use a risk factor for atypical periprosthetic/peri-implant fractures?-A metanalysis of retrospective cohort studies and systematic review of the current evidence

Pedro Ferreira et al.

Summary: This study conducted a systematic review and meta-analysis of patients taking long-term bisphosphonates, and found an association between bisphosphonate use and atypical periprosthetic/peri-implant fractures. Although there is limited research on these fractures, clinicians should be vigilant and actively search for atypical fractures in patients on long-term bisphosphonates.

ORTHOPAEDICS & TRAUMATOLOGY-SURGERY & RESEARCH (2023)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Surgical treatment of 61 consecutive patients with maxillary stage 3 medication-related osteonecrosis of the jaws using a pedicled buccal fat pad

Sanne Werner Moeller Andersen et al.

Summary: This study suggests that using the buccal fat pad (BFP) for the closure of maxillary sinus defects in stage 3 MRONJ patients is a reliable method with a high success rate. Successful surgery and prosthetic rehabilitation may improve the body weight and quality of life of patients.

ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG (2023)

Add to Collection

Article Health Care Sciences & Services

The Exosomes Containing LINC00461 Originated from Multiple Myeloma Inhibit the Osteoblast Differentiation of Bone Mesenchymal Stem Cells via Sponging miR-324-3p

Yang Wu et al.

Summary: This study found that multiple myeloma affects the osteoblast differentiation of bone marrow mesenchymal stem cells (BM-MSCs), and LINC00461 plays an important role in this process. By analyzing the expression of LINC00461 in the exosomes of multiple myeloma cells, it was found that LINC00461 can inhibit the osteoblast differentiation of BM-MSCs and suppress the activation of the Wnt/beta-catenin pathway.

JOURNAL OF HEALTHCARE ENGINEERING (2022)

Add to Collection

Article Hematology

Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins

Cristina Panaroni et al.

Summary: This study reveals that adipocytes in the bone marrow play a role in supporting multiple myeloma cells and that the lipolysis pathway is involved in this interaction. The uptake of free fatty acids by myeloma cells promotes their proliferation, while higher concentrations of fatty acids induce lipotoxicity. Blocking the uptake of fatty acids by myeloma cells could be a potential therapeutic strategy for multiple myeloma.

BLOOD (2022)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update

Salvatore L. Ruggiero et al.

Summary: This article discusses the changes and revisions in the management strategies for patients with medication-related osteonecrosis of the jaws (MRONJ). The American Association of Oral and Maxillofacial Surgeons (AAOMS) updated their position papers based on the research and experience of committee members and highlighted the current research progress.

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2022)

Add to Collection

Review Medicine, General & Internal

The Role of Sclerostin in Bone Diseases

Elias S. Vasiliadis et al.

Summary: Sclerostin is an important regulator of bone homeostasis through inhibition of the Wnt-signaling pathway and is involved in the pathogenesis of various skeletal diseases. Ongoing research highlights the therapeutic implications of sclerostin in different pathological conditions. Antisclerostin antibodies have been approved for osteoporosis treatment, and studies are being conducted to evaluate their effectiveness in other skeletal disorders and cancer.

JOURNAL OF CLINICAL MEDICINE (2022)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Osteonecrosis of the jaw among cancer patients in Denmark: risk and prognosis

N. R. Gadgaard et al.

Summary: This study investigated the occurrence and mortality of osteonecrosis of the jaw (ONJ) in patients with multiple myeloma and cancerous bone metastases treated with anti-resorptive therapy. The study found that the incidence of ONJ was 1.9% and the 5-year mortality rate was 91% among the identified patients.

INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2022)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation

Camilla Ottesen et al.

Summary: The aim of this study was to evaluate the impact of a high-dose antiresorptive drug holiday on the development of medication-related osteonecrosis of the jaw (MRONJ) after surgical tooth extraction. The results indicate that a high-dose antiresorptive drug holiday does not prevent the occurrence of MRONJ and patient-reported health state declines during the drug holiday.

ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2022)

Add to Collection

Article Oncology

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study REBUILD

Evangelos Terpos et al.

Summary: The study demonstrates that the anti-CD38 monoclonal antibody daratumumab improves bone turnover in patients with multiple myeloma by inducing bone formation and reducing osteoblast inhibition, highlighting its clinical significance.

CANCERS (2022)

Add to Collection

Review Hematology

Treatment horizon in multiple myeloma

Cinnie Yentia Soekojo et al.

Summary: This paper reviews the current and emerging therapies for multiple myeloma (MM), a complex and heterogeneous condition. The expansion in treatments, including monoclonal antibodies, antibody-drug conjugates, and other novel approaches, has led to improvements in overall survival for MM patients with immune dysfunction.

EUROPEAN JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Multidisciplinary Sciences

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma

Huan Liu et al.

Summary: This study reveals the contribution of CIITA, a major histocompatibility complex class II transactivator, expressed in osteocytes to the development of bone lesions in multiple myeloma. CIITA upregulates the secretion of osteolytic cytokines from osteocytes, leading to enhanced osteoclastogenesis and decreased osteoblastogenesis. Additionally, myeloma cell-secreted 2-deoxy-D-ribose upregulates CIITA expression in osteocytes through the STAT1/IRF1 signaling pathway.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

The role of the bone microenvironment in regulating myeloma residual disease and treatment

Terry G. G. Dadzie et al.

Summary: This article discusses the persistence of minimal residual disease in multiple myeloma patients, leading to relapse, and its relationship with the bone marrow microenvironment and bone disease. It also reviews current therapies for myeloma and myeloma bone disease and identifies novel therapeutic targets for treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Hematology

Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program

Lene Kongsgaard Nielsen et al.

Summary: Patients with multiple myeloma report high symptom burden and functional disabilities affecting their health-related quality of life. A study on rehabilitation for MM patients in remission found no change in HRQoL after a 12-week program, with pain and fatigue being the main factors contributing to impaired HRQoL. This underscores the need for evidence-based guidelines for rehabilitation and palliative care for MM patients in everyday life.

ANNALS OF HEMATOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease

Antonio Garcia-Gomez et al.

Summary: Research has shown that mesenchymal stromal cells (MSCs) isolated from the bone marrow of multiple myeloma patients exhibit altered DNA methylation patterns, and treatment with a methyltransferase inhibitor can reverse MM-associated bone loss and reduce tumor burden in MM murine models.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background

Aristea-Maria Papanota et al.

Summary: Multiple myeloma (MM) is a common hematological malignancy characterized by bone disease resulting from imbalance in bone-remodeling process. miRNAs play a crucial role in the pathophysiology of MMBD and are potential molecular targets for targeted therapy.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Endocrinology & Metabolism

Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension

Sabashini K. Ramchand et al.

Summary: Combination therapy of teriparatide and denosumab can significantly increase bone mineral density, while discontinuation of denosumab may lead to bone loss and increased fracture risk. A single dose of zoledronic acid effectively maintains the BMD improvements achieved with the combination therapy for at least 27 months. Spine BMD was largely preserved during this period as well.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Add to Collection

Review Oncology

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

Evangelos Terpos et al.

Summary: The Bone Working Group of the International Myeloma Working Group recommends the use of zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma. Denosumab can be considered for patients with renal impairment. Cement augmentation is effective for painful vertebral compression fractures.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

Evangelos Terpos et al.

Summary: Carfilzomib with dexamethasone is an effective regimen for patients with relapsed/refractory multiple myeloma, showing improvements in bone metabolism and health independent of myeloma response to treatment. The combination resulted in a low rate of skeletal-related events and significant decreases in bone resorption markers, along with increases in markers of bone formation.

CANCERS (2021)

Add to Collection

Article Oncology

Multiple Myeloma Cells Alter Adipogenesis, Increase Senescence-Related and Inflammatory Gene Transcript Expression, and Alter Metabolism in Preadipocytes

Heather Fairfield et al.

Summary: In multiple myeloma (MM), the cancer cells can alter the differentiation capacity and gene expression profiles of preadipocytes and bone marrow MSCs, leading to decreased lipid accumulation and changes in key pathways involved in metabolism and cell cycle. MM cells also induce the expression of supportive genes and exhibit a forward-feedback mechanism. Overall, MM cells manipulate the microenvironment by inhibiting adipogenic differentiation while promoting the expression of pro-myeloma molecules.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Hematology

Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study

Evangelos Terpos et al.

Summary: Denosumab showed a favorable effect on median progression-free survival in newly diagnosed multiple myeloma patients, especially in those intending to undergo ASCT and receiving proteasome inhibitor (PI)-based triplet regimens.

BLOOD ADVANCES (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Ixazomib inhibits myeloma cell proliferation by targeting UBE2K

Qingqing Wang et al.

Summary: Ixazomib inhibits the proliferation of myeloma cells by targeting UBE2K, leading to decreased cell survival and increased apoptosis in a dose-dependent manner. It also affects cell cycle, induces apoptosis, and increases the production of reactive oxygen species.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2021)

Add to Collection

Article Endocrinology & Metabolism

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

Peter Burckhardt et al.

Summary: The risk of vertebral fractures (VFs) after treatment with denosumab (Dmab) is associated with increase in bone resorption markers and bone mineral density during and after treatment. Bisphosphonates, especially after Dmab, have a protective effect against VFs. The risk of VFs is poorly predictable before Dmab prescription, but bone markers and BMD during and after treatment have predictive value.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

Add to Collection

Article Immunology

The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape

Madelon M. E. de Jong et al.

Summary: The progression and therapy response of multiple myeloma is influenced by the bone marrow niche. A study identified inflammatory mesenchymal stromal cells that interact with tumor cells, indicating a potential role in disease persistence. Tracking bone marrow inflammation over time revealed a link to disease persistence despite successful antitumor therapy.

NATURE IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: protocol for a single-blind randomised controlled trial

Line Adsboell Wickstroem et al.

Summary: Multiple myeloma patients often present with pathological fractures at diagnosis and are at risk of developing additional fractures. This study aims to assess the clinical impact of vertebroplasty on these patients to optimize fracture treatment.

BMJ OPEN (2021)

Add to Collection

Article Oncology

A Molecular Signature of Circulating MicroRNA Can Predict Osteolytic Bone Disease in Multiple Myeloma

Aristea-Maria Papanota et al.

Summary: Multiple myeloma bone disease (MMBD) is a significant complication of multiple myeloma, impacting patients' quality of life. Specific miRNAs have been identified to effectively predict the presence of MMBD in MM patients, with two of them also playing a prognostic role in MM progression.

CANCERS (2021)

Add to Collection

Review Oncology

Bone Marrow Mesenchymal Stromal Cells in Multiple Myeloma: Their Role as Active Contributors to Myeloma Progression

Patricia Maiso et al.

Summary: Multiple myeloma is a cancer of plasma cells that accumulate in the bone marrow, and the interaction between mesenchymal stromal cells and myeloma cells appears to play a crucial role in the progression of the disease. Structural and functional differences between mesenchymal stromal cells from healthy donors and myeloma patients have been identified, suggesting a significant contribution to the pathophysiology of multiple myeloma.

CANCERS (2021)

Add to Collection

Review Cell Biology

The Roadmap of RANKL/RANK Pathway in Cancer

Sandra Casimiro et al.

Summary: The RANKL/RANK pathway plays a crucial role in bone remodeling, breast carcinogenesis, and immune modulation. Targeting RANKL with therapies may hold promise in the treatment of bone metastatic diseases, breast cancer, and improving response to immunotherapy in certain cancers.

CELLS (2021)

Add to Collection

Review Medicine, General & Internal

Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)

Sven Otto et al.

Summary: MRONJ, a well-known side effect of antiresorptive and antiangiogenic drugs, is believed to have a strong association with local infection in its pathogenesis.

MEDICINA-LITHUANIA (2021)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Apical surgery in cancer patients receiving high-dose antiresorptive medication-a retrospective clinical study with a mean follow-up of 13 months

Sanne Werner Moeller Andersen et al.

Summary: The study evaluated the results of apical surgery in patients receiving high-dose antiresorptive medication and found it to be a valid treatment option for apical periodontitis. None of the patients developed medication-related osteonecrosis of the jaw, indicating a positive outcome. Further research with larger study groups and longer follow-up periods is recommended.

ORAL AND MAXILLOFACIAL SURGERY-HEIDELBERG (2021)

Add to Collection

Article Oncology

Multiple myeloma BM-MSCs increase the tumorigenic ty of MM cells via transfer of VLA4-enriched microvesicles

Mahmoud Dabbah et al.

CARCINOGENESIS (2020)

Add to Collection

Article Endocrinology & Metabolism

A comparative effectiveness pilot study of teriparatide for medication-related osteonecrosis of the jaw: daily versus weekly administration

Y. Ohbayashi et al.

OSTEOPOROSIS INTERNATIONAL (2020)

Add to Collection

Letter Hematology

Characterization of freshly isolated bone marrow mesenchymal stromal cells from healthy donors and patients with multiple myeloma: transcriptional modulation of the microenvironment

Daniel Alameda et al.

HAEMATOLOGICA (2020)

Add to Collection

Letter Oncology

Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Maria Gavriatopoulou et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Oncology

Ixazomib Improves Bone Remodeling and Counteracts Sonic Hedgehog Signaling Inhibition Mediated by Myeloma Cells

Daniele Tibullo et al.

CANCERS (2020)

Add to Collection

Review Clinical Neurology

Percutaneous vertebroplasty as treatment of malignant vertebral lesions: a systematic review and GRADE evaluation resulting in a Danish national clinical guideline

Rikke Rousing et al.

EUROPEAN SPINE JOURNAL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma

Lea Lemaitre et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Endocrinology & Metabolism

Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial

Anne Sophie Solling et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis A Population-Based Cohort Study

Houchen Lyu et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Oncology

Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

Ie-Wen Sim et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates

Dennis M. Black et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Endocrinology & Metabolism

Adjuvant therapies for MRONJ: A systematic review

Dries Govaerts et al.

BONE (2020)

Add to Collection

Article Medical Laboratory Technology

BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner

Amjd Ibraheem et al.

TRANSLATIONAL RESEARCH (2019)

Add to Collection

Article Oncology

The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG)

Charalampia Kyriakou et al.

BLOOD CANCER JOURNAL (2019)

Add to Collection

Article Multidisciplinary Sciences

Transcriptome Analysis of Mesenchymal Stem Cells from Multiple Myeloma Patients Reveals Downregulation of Genes Involved in Cell Cycle Progression, Immune Response, and Bone Metabolism

Rodrigo Carlini Fernando et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Hematology

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells

Weng Hua Khoo et al.

BLOOD (2019)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Workshop of European task force on medication-related osteonecrosis of the jaw-Current challenges

Morten Schiodt et al.

ORAL DISEASES (2019)

Add to Collection

Article Hematology

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

Evangelos Terpos et al.

AMERICAN JOURNAL OF HEMATOLOGY (2019)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study

Oliver Ristow et al.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2019)

Add to Collection

Article Endocrinology & Metabolism

Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance

E. M. Stein et al.

OSTEOPOROSIS INTERNATIONAL (2019)

Add to Collection

Article Endocrinology & Metabolism

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Steven R. Cummings et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2018)

Add to Collection

Article Hematology

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study

Kara-Louise Royle et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Oncology

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

Carolina Schinke et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Can Autofluorescence Guide Surgeons in the Treatment of Medication-Related Osteonecrosis of the Jaw? A Prospective Feasibility Study

Amerigo Giudice et al.

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2018)

Add to Collection

Article Oncology

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Can platelet-rich fibrin improve healing after surgical treatment of medication-related osteonecrosis of the jaw? A pilot study

Amerigo Giudice et al.

ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2018)

Add to Collection

Review Immunology

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

Niels W. C. J. van de Donk et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Comparison of auto-fluorescence and tetracycline fluorescence for guided bone surgery of medication-related osteonecrosis of the jaw: a randomized controlled feasibility study

O. Ristow et al.

INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2017)

Add to Collection

Article Medicine, General & Internal

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases A Randomized Clinical Trial

Andrew L. Himelstein et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Role of microbiological culture and polymerase chain reaction (PCR) of actinomyces in medication-related osteonecrosis of the jaw (MRONJ)

Sappasith Panya et al.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2017)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?

Jung-Hyun Park et al.

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2017)

Add to Collection

Article Oncology

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth

J. Delgado-Calle et al.

LEUKEMIA (2017)

Add to Collection

Article Oncology

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4Weeks inWomen With Breast Cancer Metastatic to Bone The OPTIMIZE-2 Randomized Clinical Trial

Gabriel N. Hortobagyi et al.

JAMA ONCOLOGY (2017)

Add to Collection

Review Oncology

The proteasome and proteasome inhibitors in multiple myeloma

Sara Gandolfi et al.

CANCER AND METASTASIS REVIEWS (2017)

Add to Collection

Article Oncology

Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation

Mahmoud Dabbah et al.

CARCINOGENESIS (2017)

Add to Collection

Article Hematology

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma

Michelle M. McDonald et al.

BLOOD (2017)

Add to Collection

Article Oncology

Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients

Agustin Aviles et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2017)

Add to Collection

Article Oncology

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation

Juraj Adamik et al.

MOLECULAR CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing

Karan Malhotra et al.

BMC CANCER (2016)

Add to Collection

Article Endocrinology & Metabolism

Contact of myeloma cells induces a characteristic transcriptome signature in skeletal precursor cells-Implications for myeloma bone disease

Julia Dotterweich et al.

BONE (2016)

Add to Collection

Article Oncology

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma

Jesus Delgado-Calle et al.

CANCER RESEARCH (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Effectiveness of percutaneous vertebroplasty in patients with multiple myeloma having vertebral pain

Omer Fatih Nas et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - A prospective study over 6 years

Thomas Mucke et al.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2016)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Effectiveness of percutaneous vertebroplasty in patients with multiple myeloma having vertebral pain

Omer Fatih Nas et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)

Add to Collection

Article Orthopedics

Comparison if the addition of multilevel vertebral augmentation to conventional therapy will improve the outcome of patients with multiple myeloma

Ziad A. Audat et al.

SCOLIOSIS AND SPINAL DISORDERS (2016)

Add to Collection

Article Hematology

Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

Ramon Garcia-Sanz et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Dentistry, Oral Surgery & Medicine

Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?

Sven Otto et al.

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY (2015)

Add to Collection

Article Multidisciplinary Sciences

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

Michelle A. Lawson et al.

NATURE COMMUNICATIONS (2015)

Add to Collection

Article Hematology

Zoledronic acid as compared with observation in multiple myeioma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial

Ramon Garcia-Sanz et al.

HAEMATOLOGICA (2015)

Add to Collection

Article Oncology

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma

K. M. Sanfilippo et al.

LEUKEMIA & LYMPHOMA (2015)

Add to Collection

Article Oncology

Risk of disability pension for patients diagnosed with haematological malignancies: A register-based cohort study

Trine A. Horsboel et al.

ACTA ONCOLOGICA (2014)

Add to Collection

Article Pathology

Osteoblast Recruitment Routes in Human Cancellous Bone Remodeling

Helene B. Kristensen et al.

AMERICAN JOURNAL OF PATHOLOGY (2014)

Add to Collection

Article Oncology

Preclinical Activity of the Oral Proteasome Inhibitor MLN9708 in Myeloma Bone Disease

Antonio Garcia-Gomez et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Review Multidisciplinary Sciences

Incidence and Risk of Cardiotoxicity Associated with Bortezomib in the Treatment of Cancer: A Systematic Review and Meta-Analysis

Yi Xiao et al.

PLOS ONE (2014)

Add to Collection

Article Oncology

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease

Antonio Garcia-Gomez et al.

ONCOTARGET (2014)

Add to Collection

Review Health Care Sciences & Services

Role of osteocytes in multiple myeloma bone disease

Jesus Delgado-Calle et al.

CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE (2014)

Add to Collection

Article Hematology

The impact of response on bone-directed therapy in patients with multiple myeloma

Alessandra Larocca et al.

BLOOD (2013)

Add to Collection

Article Hematology

Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease

Ida B. Kristensen et al.

BRITISH JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Article Hematology

Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration

Ida B. Kristensen et al.

EUROPEAN JOURNAL OF HAEMATOLOGY (2013)

Add to Collection

Article Oncology

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma-Related Bone Disease

Evangelos Terpos et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

Add to Collection

Article Oncology

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects

M. A. Hurchla et al.

LEUKEMIA (2013)

Add to Collection

Article Multidisciplinary Sciences

Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells

Thibaud Andre et al.

PLOS ONE (2013)

Add to Collection

Article Oncology

The Saxon Bisphosphonate Register - Therapy and prevention of bisphosphonate-related osteonecrosis of the jaws

Marika Schubert et al.

ORAL ONCOLOGY (2012)

Add to Collection

Article Multidisciplinary Sciences

Sclerostin is overexpressed by plasma cells from multiple myeloma patients

Giacomina Brunetti et al.

SKELETAL BIOLOGY AND MEDICINE I (2011)

Add to Collection

Review Endocrinology & Metabolism

Biochemical and molecular mechanisms of action of bisphosphonates

Michael J. Rogers et al.

BONE (2011)

Add to Collection

Article Oncology

Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial

James Berenson et al.

LANCET ONCOLOGY (2011)

Add to Collection

Article Hematology

Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project

Milena Sant et al.

BLOOD (2010)

Add to Collection

Letter Hematology

Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma

Thomas Lund et al.

BRITISH JOURNAL OF HAEMATOLOGY (2010)

Add to Collection

Article Hematology

Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells

Thomas L. Andersen et al.

BRITISH JOURNAL OF HAEMATOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Gareth J. Morgan et al.

LANCET (2010)

Add to Collection

Article Medicine, General & Internal

Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial

Caroline A. H. Klazen et al.

LANCET (2010)

Add to Collection

Article Oncology

Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease

E. Terpos et al.

LEUKEMIA (2010)

Add to Collection

Article Pathology

A Physical Mechanism for Coupling Bone Resorption and Formation in Adult Human Bone

Thomas Levin Andersen et al.

AMERICAN JOURNAL OF PATHOLOGY (2009)

Add to Collection

Article Oncology

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

M. Garayoa et al.

LEUKEMIA (2009)

Add to Collection

Article Clinical Neurology

Balloon kyphoplasty in the treatment of metastatic disease of the spine: a 2-year prospective evaluation

R. Pflugmacher et al.

EUROPEAN SPINE JOURNAL (2008)

Add to Collection

Article Endocrinology & Metabolism

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

Ana O. Hoff et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2008)

Add to Collection

Article Oncology

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

Mehmet Sonmez et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2008)

Add to Collection

Article Oncology

Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates

Vittorio Montefusco et al.

LEUKEMIA & LYMPHOMA (2008)

Add to Collection

Review Medicine, General & Internal

Bisphosphonates: Mechanism of action and role in clinical practice

Mathew T. Drake et al.

MAYO CLINIC PROCEEDINGS (2008)

Add to Collection

Article Oncology

Bone marrow mesenchymal stem cells are abnormal in multiple myeloma

J. Corre et al.

LEUKEMIA (2007)

Add to Collection

Article Clinical Neurology

Quantitative sensory findings in patients with bortezomib-induced pain

Juan P. Cata et al.

JOURNAL OF PAIN (2007)

Add to Collection

Review Rheumatology

Biology of RANK, RANKL, and osteoprotegerin

Brendan F. Boyce et al.

ARTHRITIS RESEARCH & THERAPY (2007)

Add to Collection

Article Oncology

Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma

B. Arnulf et al.

LEUKEMIA (2007)

Add to Collection

Article Hematology

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

Evangelos Terpos et al.

BRITISH JOURNAL OF HAEMATOLOGY (2006)

Add to Collection

Article Oncology

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

Marianna C. Politou et al.

INTERNATIONAL JOURNAL OF CANCER (2006)

Add to Collection

Article Oncology

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

Paul G. Richardson et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

Article Biochemistry & Molecular Biology

A role of TRAIL in killing osteoblasts by myeloma cells

I Tinhofer et al.

FASEB JOURNAL (2006)

Add to Collection

Article Hematology

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

N Giuliani et al.

BLOOD (2005)

Add to Collection

Article Biochemistry & Molecular Biology

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

I Zavrski et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)

Add to Collection

Letter Hematology

Evaluation and prognostic value of serum osteoprotegerin in multiple myeloma

S Depil et al.

BRITISH JOURNAL OF HAEMATOLOGY (2005)

Add to Collection

Article Hematology

IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells

JW Lee et al.

BLOOD (2004)

Add to Collection

Article Oncology

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma - A randomized, double-blind, multicenter, comparative trial

LS Rosen et al.

CANCER (2003)

Add to Collection

Article Hematology

Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease

F Silvestris et al.

BRITISH JOURNAL OF HAEMATOLOGY (2003)

Add to Collection

Article Medicine, General & Internal

Review of 1027 patients with newly diagnosed multiple myeloma

RA Kyle et al.

MAYO CLINIC PROCEEDINGS (2003)

Add to Collection

Article Hematology

Human myeloma cells stimulate the receptor activator of nuclear factor-κB ligand (RANKL) in T lymphocytes:: a potential role in multiple myeloma bone disease

N Giuliani et al.

BLOOD (2002)

Add to Collection

Article Hematology

Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells

T Standal et al.

BLOOD (2002)

Add to Collection

Article Oncology

Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma

S Dudeney et al.

JOURNAL OF CLINICAL ONCOLOGY (2002)

Add to Collection

Article Hematology

RANK (receptor activator of nuclear factor-κB) and RANKL expression in multiple myeloma

S Roux et al.

BRITISH JOURNAL OF HAEMATOLOGY (2002)

Add to Collection

Article Multidisciplinary Sciences

Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression

RN Pearse et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Add to Collection

Article Endocrinology & Metabolism

Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers

EM Hauge et al.

JOURNAL OF BONE AND MINERAL RESEARCH (2001)

Add to Collection

Article Oncology

Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials

P Major et al.

JOURNAL OF CLINICAL ONCOLOGY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.